2,153 Shares in DaVita Inc. (NYSE:DVA) Bought by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC purchased a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,153 shares of the company's stock, valued at approximately $322,000.

Several other institutional investors have also modified their holdings of DVA. Invesco Ltd. lifted its stake in DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after acquiring an additional 275,284 shares in the last quarter. JPMorgan Chase & Co. increased its stake in DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Amundi grew its position in shares of DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares during the last quarter. Epoch Investment Partners Inc. acquired a new stake in DaVita during the 4th quarter worth $55,100,000. Finally, KBC Group NV boosted its stake in DaVita by 0.8% in the fourth quarter. KBC Group NV now owns 316,155 shares of the company's stock valued at $47,281,000 after acquiring an additional 2,636 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Trading Up 0.9 %

NYSE DVA traded up $1.22 during trading hours on Tuesday, hitting $142.79. 828,059 shares of the company's stock were exchanged, compared to its average volume of 822,703. DaVita Inc. has a 12-month low of $131.44 and a 12-month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The business's 50 day moving average is $145.95 and its 200-day moving average is $154.35. The firm has a market capitalization of $10.98 billion, a P/E ratio of 13.30, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DVA. Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Barclays upped their target price on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to MarketBeat, DaVita has an average rating of "Hold" and a consensus target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.